TY  - EJOU
AU  - WANG, QIANG 
AU  - ZHAO, GUO 
AU  - XIE, LONGXIANG 
AU  - LI, XUAN 
AU  - YU, XIXI 
AU  - LI, QIONGSHAN 
AU  - ZHENG, BAOPING 
AU  - WUSIMAN, ZULIPINUER 
AU  - GUO, XIANGQIAN 

TI  - dbSCI: A manually curated database of SARS-CoV-2 inhibitors for COVID-19
T2  - BIOCELL

PY  - 2023
VL  - 47
IS  - 2
SN  - 1667-5746

AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen of the ongoing coronavirus disease 2019 (COVID-19) global pandemic. Here, by centralizing published cell-based experiments, clinical trials, and virtual drug screening data from the NCBI PubMed database, we developed a database of SARS-CoV-2 inhibitors for COVID-19, dbSCI, which includes 234 SARS-CoV-2 inhibitors collected from publications based on cell-based experiments, 81 drugs of COVID-19 in clinical trials and 1305 potential SARS-CoV-2 inhibitors from bioinformatics analyses. dbSCI provides four major functions: (1) search the drug target or its inhibitor for SARS-CoV-2, (2) browse target/inhibitor information collected from cell experiments, clinical trials, and virtual drug screenings, (3) download, and (4) submit data. Each entry in dbSCI contains 18 types of information, including inhibitor/drug name, targeting protein, mechanism of inhibition, experimental technique, experimental sample type, and reference information. In summary, dbSCI provides a relatively comprehensive, credible repository for inhibitors/drugs against SARS-CoV-2 and their potential targeting mechanisms and it will be valuable for further studies to control COVID-19.
KW  - SARS-CoV-2; COVID-19; Inhibitors; Drugs; Database

DO  - 10.32604/biocell.2023.025310